

Dear Shareholder

1 July 2019

## Amplia Therapeutics Limited (Amplia) – Non- Renounceable Rights Issue

On 28 June 2019, Amplia announced a non-renounceable rights issue of approximately 22,311,652 new fully paid ordinary shares (**Rights Issue**) under which its eligible shareholders will be offered 1 fully paid ordinary share in Amplia (**New Share**) for every 2 fully paid ordinary shares held on the record date, at an issue price of A\$0.10 or NZ\$0.11 per New Share. The Rights Issue is not underwritten.

Each subscriber under the Rights Issue will receive one free attaching option (**Option**) for every two New Shares subscribed for under the Rights Issue. The Options will have an exercise price of A\$0.15 and an expiry date of 30 June 2022. Amplia will not apply for quotation of the Options and accordingly the Options will not be listed on ASX.

The Rights Issue is being carried out pursuant to a transaction-specific prospectus issued under section 713 of the *Corporations Act 2001* (Cth) (**Corporations Act**) which was lodged with the Australian Securities and Investments Commission and ASX on 28 June 2019 (**Prospectus**). The Prospectus is available from ASX's website ([www.asx.com.au](http://www.asx.com.au)) and Amplia's website ([www.ampliatx.com](http://www.ampliatx.com)).

This Rights Issue offer will be made to those shareholders of Amplia with registered addresses in Australia and New Zealand only (**Eligible Shareholders**) who are registered as holders of shares on the record date for the Rights Issue, being Wednesday, 3 July 2019. Eligible Shareholders will be able to apply for New Shares in excess of their entitlement, subject to scale-back at Amplia's discretion.

Eligible Shareholders should read the Prospectus carefully and in its entirety before deciding whether to participate in the Rights Issue. Eligible Shareholders who wish to participate should follow the instructions on your personalised Entitlement and Acceptance Form accompanying the Prospectus. If you choose to do nothing in respect of your entitlement, your entitlement will lapse, you will not receive any New Shares and your interest in Amplia will be diluted.

If fully subscribed, the Rights Issue will raise approximately \$2.23 million before costs. The proceeds of the Rights Issue, together with the net proceeds of the Company's \$360,000 share placement that completed on 14 June 2019, will be used to complete the remaining studies that are required before commencement of the Phase I healthy volunteer trial of drug candidate AMP945, as well as providing the Company with additional working capital.

Amplia has determined that it is unreasonable to make the offer generally available to shareholders with registered addresses outside of Australia and New Zealand (**Ineligible Shareholders**) due to:

1. the small number of shareholders with registered addresses outside of these countries; and
2. the cost of complying with the legal and other regulatory requirements in each of the countries concerned.

The Rights Issue will not be extended to Ineligible Shareholders and they will not receive a copy of the Prospectus or an Entitlement and Acceptance Form. Ineligible Shareholders are not required to take any action in relation to this letter, but there may be financial implications for you as a result of the Rights Issue that you should be aware of.

No action has been taken to register or qualify the Prospectus and Entitlement and Acceptance Form, the Rights Issue or the New Shares or to otherwise permit a public offering of the New Shares in any jurisdiction outside of Australia or New Zealand.

Amplia expects to despatch the Prospectus and Entitlement and Acceptance Forms to Eligible Shareholders on or around 8 July 2019.

The expected key dates for the Rights Issue are set out below:

<b>Event</b>	<b>Date</b>
Lodgement of Prospectus with ASIC and ASX and Appendix 3B with ASX	Friday 28 June 2019
Ex-Entitlement Date	Tuesday 2 July 2019
<b>Record Date for the Rights Issue</b>	Wednesday 3 July 2019
Mailing of Prospectus and Entitlement and Acceptance Form to Eligible Shareholders	Monday 8 July 2019
<b>Rights Issue opening date</b>	Monday 8 July 2019
<b>Rights Issue closing date</b> – last date for receipt of acceptances and payment of application money in full	Friday 26 July 2019
Announces Rights Issue shortfall to ASX	Wednesday 31 July 2019
Issue of New Shares under the Rights Issue and completion of despatch of holding statements and CHES notices	Friday 2 August 2019
Normal trading of New Shares issued under the Rights Issue expected to commence on ASX	Monday 5 August 2019

This timetable is indicative only and may be subject to change, subject to the ASX Listing Rules. Amplia reserves the right to amend any or all of these dates and times without notice, subject to the ASX Listing Rules, the Corporations Act and other applicable laws.

Existing option holders may participate in the Rights Issue upon exercise of their vested options. Amplia sent a letter to its option holders on 28 June 2019 to notify them of their right to participate in the Rights Issue upon exercise of their vested options.

For further information about the Rights Issue please email [info@ampliatx.com](mailto:info@ampliatx.com)

Yours faithfully



**Andrew J. Cooke**  
**Director and Company Secretary**  
**Amplia Therapeutics Limited**